Molecular Theranostics (United States)
- World rank, 2022–2025
- #23,875 of 28,054
- Rank in United States
- #3,590 of 4,192
- Research works
- 119 ▲ 167% vs 2013–17
- Citations
- 1.7k 14.4 per fractional work
- Top-10% rate
- 22.5% record average 16.5%
- Open access
- 58% world 28%
What does Molecular Theranostics (United States) specialise in?
Where its research is concentrated relative to its size: Medicine takes 3.4× the share of its output that it takes of world research.
- MedicineField · 40.3 works3.4×
Location quotient, a volume reading rather than an impact one. It surfaces small, lopsided specialities.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Pharmacology, Toxicology and Pharmaceutics, 4.3×. Every wedge is a field page.
- Pharmacology, Toxicology and Pharmaceutics 4.3×
- Medicine 3.4×
- Biochemistry, Genetics and Molecular Biology 2.7×
- Immunology and Microbiology 1.2×
- Nursing 0.9×
- Materials Science 0.9×
- Neuroscience 0.8×
- Chemical Engineering 0.7×
- Engineering 0.6×
- Chemistry 0.5×
- Decision Sciences 0.3×
- Arts and Humanities 0.2×
- Energy 0.1×
- Agricultural and Biological Sciences 0.1×
- Computer Science 0.1×
- Psychology 0.1×
- Mathematics 0.1×
- Physics and Astronomy 0.1×
- Environmental Science 0.0×
- Dentistry 0.0×
- Health Professions 0.0×
- Economics, Econometrics and Finance 0.0×
- Social Sciences 0.0×
Which keywords describe research at Molecular Theranostics (United States)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Prostate Cancer, Immunotherapy, PET Imaging, Genetic Mutations, Clinical Trials, Targeted Therapy, Biomarkers and Genomic Profiling.
- Regenerative Medicine
- Cell Culture
- Cancer Progression
- Hydrogels
- PET/CT
- Imaging
- N-terminal Acetylation
- Screening
- Gleason Grading
- Biopsy
- Clinical Guidelines
- Cancer
- Angiogenesis
- Radioimmunotherapy
- Metastatic Prostate Cancer
- Androgen Receptor
- Genomic Profiling
- Targeted Therapy
- Genetic Mutations
- Immunotherapy
- Prostate Cancer
- PET Imaging
- Clinical Trials
- Biomarkers
- Cancer Treatment
- Hormone Therapy
- Dosimetry
- Radiopharmaceuticals
- Cancer Therapy
- Tumor Microenvironment
- Immunosuppression
- Genetic Variants
- Radiation Therapy
- Fibroblast Activation Protein
- Quantitative
- Tissue Engineering
- tumor
- Metastasis
- Bioprinting
- Microfluidic Devices
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Prostate Cancer10▲ 129×3 topics
- Immunotherapy10▲ 23×12 topics
- PET Imaging10▲ 95×3 topics
- Genetic Mutations9▲ 34×7 topics
- Clinical Trials9▲ 21×6 topics
- Targeted Therapy9▲ 63×4 topics
- Biomarkers8▲ 20×6 topics
- Genomic Profiling8▲ 123×2 topics
- Cancer Treatment8▲ 52×4 topics
- Androgen Receptor7▲ 160×1 topic
- Hormone Therapy7▲ 144×2 topics
- Metastatic Prostate Cancer7▲ 289×1 topic
- Dosimetry7▲ 159×2 topics
- Radioimmunotherapy7▲ 392×1 topic
- Radiopharmaceuticals7▲ 392×1 topic
- Angiogenesis5▲ 23×7 topics
- Cancer Therapy4▲ 13×8 topics
- Cancer4▲ 5.2×11 topics
- Tumor Microenvironment4▲ 16×5 topics
- Clinical Guidelines3▲ 18×3 topics
- Immunosuppression3▲ 56×2 topics
- Biopsy3▲ 79×2 topics
- Genetic Variants3▲ 28×2 topics
- Gleason Grading3▲ 121×1 topic
- Radiation Therapy3▲ 37×2 topics
- Screening3▲ 51×1 topic
- Fibroblast Activation Protein3▲ 107×1 topic
- N-terminal Acetylation3▲ 107×1 topic
- Quantitative3▲ 51×2 topics
- Imaging3▲ 17×4 topics
- Tissue Engineering3▲ 6.9×5 topics
- PET/CT2▲ 69×1 topic
- tumor2▲ 69×1 topic
- Hydrogels2▲ 19×3 topics
- Metastasis2▲ 9.9×5 topics
- Cancer Progression2▲ 16×5 topics
- Bioprinting2▲ 48×1 topic
- Cell Culture2▲ 26×2 topics
- Microfluidic Devices2▲ 24×1 topic
- Regenerative Medicine2▲ 11×2 topics
Which research topics does Molecular Theranostics (United States) publish most on?
By volume in 2022–2025: Prostate Cancer Treatment and Research, Radiopharmaceutical Chemistry and Applications, Prostate Cancer Diagnosis and Treatment and Peptidase Inhibition and Analysis.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Prostate Cancer Treatment and Research Pulmonary and Respiratory Medicine 7 works
- 2 Radiopharmaceutical Chemistry and Applications Radiology, Nuclear Medicine and Imaging 7 works
- 3 Prostate Cancer Diagnosis and Treatment Pulmonary and Respiratory Medicine 3 works
- 4 Peptidase Inhibition and Analysis Oncology 3 works
- 5 Medical Imaging Techniques and Applications Radiology, Nuclear Medicine and Imaging 2 works
- 6 3D Printing in Biomedical Research Biomedical Engineering 2 works
- 7 Protease and Inhibitor Mechanisms Cancer Research 1 works
- 8 Neuroendocrine Tumor Research Advances Epidemiology 1 works
- 9 Cancer, Lipids, and Metabolism Cancer Research 1 works
- 10 Radiomics and Machine Learning in Medical Imaging Radiology, Nuclear Medicine and Imaging 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Molecular Theranostics (United States)'s research output changed?
Output in 2018–2022 was 167% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Cleveland
- Case Western Reserve University
- Cleveland Clinic
- Glenn Research Center
- Cleveland State University
- University Hospitals of Cleveland
- University School
- Cleveland Clinic Lerner College of Medicine
- Cleveland Foundation
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.